CRSP - CRISPR Therapeutics AG
| Previous Close | 66.03 |
| Open | 66.14 |
| Bid | 65.33 x 1100 |
| Ask | 66.00 x 800 |
| Day's Range | 64.35 - 67.37 |
| 52 Week Range | 22.22 - 74.00 |
| Volume | 739,814 |
| Avg. Volume | 958,193 |
| Market Cap | 3.7B |
| Beta (5Y Monthly) | 3.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings Date | Feb 24, 2020 - Feb 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.50 |
- Zacks
What the Tech?
Let's REALLY dive deep into the abyss which can be tech. Associate Stock Strategist Dan Laboe, Zacks' resident Tech geek joins us.
- Insider Monkey
Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Zacks
Find Strong Stocks Heading into 2020 with this First Profit Screen
Find Strong Stocks Heading into 2020 with this First Profit Screen
- Zacks
Trade of the 2020's: Sell Gold, Buy Biotech
In 5 years, you be selling your gold and buying more companies leading the century of biology.
- Zacks
Biotech Tops in November: Best ETFs & Stocks
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
- Zacks
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
- Zacks
Why Gold is Headed to Zero -- And What You Should Buy Instead
Why Gold is Headed to Zero -- And What You Should Buy Instead
- GlobeNewswire
CRISPR Therapeutics to Present at Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
- Zacks
Why Biotech ETFs Surged in Monday's Trading Session
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.
- Zacks
Genomics ETFs Surge on CRISPR's Gene Editing Progress
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
- Investor's Business Daily
Crispr Therapeutics Stock Surged; Was It A Sell?
Swing trading usually focuses on small gains but can see outsized gains with good news. CRISPR Therapeutics stock gives a recent example.
- InvestorPlace
Consider Adding New Positions in U.S. Cannabis Stocks
It's looking like cannabis stocks just might have bottomed out, and it has been a long time coming. In this week's episode of "Moneyline," Matt McCall wants investors to know that if they have a long-term perspective, the fundamentals really do matter. That's why he's still confident in pot despite its serious shellacking.Well, why's that? Just this week, the U.S. House of Representative's Judiciary Committee approved a bill that legalizes marijuana at the federal level. Many analysts say it's likely the bill will pass the Democrat-controlled House, but it faces a tougher battle in the Senate. But that doesn't matter. The existence of the bill itself is still a good sign for cannabis investors. McCall is declaring 2020 the year of cannabis -- politicians just need to wake up. He argues such legislation would essentially solve the vaping crisis and clear up issues with black-market marijuana.So how can investors play this week's good news? Start with U.S. cannabis companies. Take a look at Charlotte's Web (OTCMKTS:CWBHF) and Acreage Holdings (OTCMKTS:ACRGF). Those companies, along with a few others, are reporting annualized revenue between $100 million and $200 million. McCall says now is a perfect opportunity to build on existing positions in these names or add new ones, as these stocks have bright futures ahead. And while he's still a fan of the big Canadian names, there are better opportunities to get lit right now.InvestorPlace - Stock Market News, Stock Advice & Trading Tips McCall's PodcastThere's another emerging trend that McCall is big on: biotech stocks. There's one name in particular, Crispr Therapeutics (NASDAQ:CRSP), that's making big waves. CRSP stock is up an amazing 120% year-to-date -- and McCall identified this name earlier in 2019 as part of his Early Stage Investing portfolio for its potential in gene editing. * 7 Companies Using Artificial Intelligence to Outperform the Market This week's news easily justified CRSP's place in that portfolio. On Nov. 19, Crispr announced that patients receiving its CTX001 gene-editing therapy were experiencing significant benefits. This therapy is specifically designed for patients with severe blood disorders, and works by singling out and editing affected cells. One patient living with a form of beta thalassemia had been dependent on blood transfusions, receiving as many as 16 a year. After nine months with CTX001, that patient is now considered transfusion independent.McCall is particularly interested in the treatment's use in patients with sickle cell disease, a blood disorder that causes severe pain. And based on his recent travels to Lisbon, Portugal, healthcare will soon evolve to cure these diseases. In the future, he believes they'll even be cured at the embryonic level.So what else did he learn in Portugal? Tune in to "Moneyline" for more on his travels and the future of healthcare as it relates to artificial intelligence.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Using Artificial Intelligence to Outperform the Market * 7 Earnings Reports to Watch Next Week * 6 Retail Stocks Dropping Hard Ahead of Black Friday The post Consider Adding New Positions in U.S. Cannabis Stocks appeared first on InvestorPlace.
- Zacks
Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi
The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.
- Benzinga
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...
- GlobeNewswire
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 20, 2019 -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines.
- Barrons.com
Crispr Therapeutics Rises After Company Announces Stock Sale
Shares of the biotech company are rising in early trading after the company proposed offering an additional 4.25 million common shares for sale.
- Zacks
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
- Zacks
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
- Benzinga
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
- Investor's Business Daily
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Shares of Crispr Therapeutics jumped Tuesday after the biotech company's gene-editing approach to sickle cell disease and beta thalassemia, both blood diseases, showed early promise.
- GlobeNewswire
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of 4,250,000 common shares. In addition, the underwriters will have a 30-day option to purchase up to 637,500 additional common shares at the public offering price less the underwriting discount. Goldman Sachs & Co. LLC, Piper Jaffray & Co. and Jefferies LLC are acting as joint book-running managers for the offering.
- TheStreet.com
[video]Shares of CRISPR Therapeutics Fall in After Hours Trading on Share Offering
Shares of CRISPR Therapeutics AG fell in after-hours trading Tuesday after the gene-therapy company announced a public offering of 4.25 million shares. The decline followed a sharp rise in the regular session sparked by positive initial results in an early-stage trial of a gene therapy for blood diseases including sickle cell anemia.
